Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics

Published 07/10/2022, 16:21
Updated 07/10/2022, 17:10
© Reuters.  PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics

  • PureTech Health plc (NASDAQ: PRTC) has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ: NKTR).
  • In April, Nektar Therapeutics announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team.
  • Nektar and Bristol Myers Squibb Co (NYSE: BMY) jointly decided to end the global clinical development program for bempegaldesleukin after disappointing renal cell carcinoma and bladder cancer studies.
  • Responding to press speculation, PureTech said it has exchanged indicative, non-binding proposals with Nektar Therapeutics regarding a possible combination, which may include an offer for the share capital of PureTech.
  • “PureTech and Nektar remain in discussions regarding the proposal. There can be no certainty that any firm offer will be made, nor as to the terms of any such offer. A further announcement will be made as and when appropriate,” the company said.
  • Nektar will have until Nov. 3 to make a formal offer.
  • Price Action: PRTC shares are down 20.03% at $24.80, and NKTR shares are down 1.03% at $3.34 on the last check Friday.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.